Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-25-013137
Filing Date
2025-04-25
Accepted
2025-04-25 16:16:03
Documents
20
Period of Report
2025-06-10

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A eton20250423_def14a.htm   iXBRL DEF 14A 574198
6 a01.jpg GRAPHIC 123999
7 a02.jpg GRAPHIC 119632
8 a03.jpg GRAPHIC 192461
9 a04.jpg GRAPHIC 94189
10 image01.jpg GRAPHIC 2465
  Complete submission text file 0001437749-25-013137.txt   2465526

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA eton-20241231.xsd EX-101.SCH 4578
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eton-20241231_def.xml EX-101.DEF 1750
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eton-20241231_lab.xml EX-101.LAB 1775
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eton-20241231_pre.xml EX-101.PRE 714
23 EXTRACTED XBRL INSTANCE DOCUMENT eton20250423_def14a_htm.xml XML 105590
Mailing Address 21925 W. FIELD PARKWAY SUITE 235 DEER PARK IL 60010-7278
Business Address 21925 W. FIELD PARKWAY SUITE 235 DEER PARK IL 60010-7278 (847) 787-7361
Eton Pharmaceuticals, Inc. (Filer) CIK: 0001710340 (see all company filings)

EIN.: 371858472 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38738 | Film No.: 25874274
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)